BT
Therapeutic Areas
ARS Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| neffy (epinephrine nasal spray) | Emergency treatment of severe allergic reactions (Type I), including anaphylaxis | Approved |
| Intranasal Epinephrine (ARS-1) | Acute flares of urticaria (hives) | Research/Pre-clinical |
Leadership Team at ARS Pharmaceuticals
RL
Richard Lowenthal
President and Chief Executive Officer and Director
ST
Sarina Tanimoto
Chief Medical Officer
EK
Eric Karas
Chief Commercial Officer
KS
Kathleen Scott
Chief Financial Officer
JC
Justin Chakma
Chief Business Officer
AF
Alexander Fitzpatrick
Chief Legal Officer
RB
Robert Bell
Co-Founder & Chief Science Officer
LH
Lynda Harris
Vice President, Human Resources
DR
Daniel Relovsky
Senior Vice President, Marketing
PS
Pratik Shah
Director and Chair of the Board